logo-loader
RNS
viewAstraZeneca

Total Voting Rights

/**/ em{letter-spacing:.5pt;border:none windowtext 1.0pt;padding:0cm;font-weight:bold;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: purple } .ap{size:21.0cm 842.0pt;margin:3.0cm 72.0pt 0cm 72.0pt;}div.ap{}p.cb{margin:0cm;margin-bottom:.0001pt;line-height:120%;text-autospace:none;font-size:11.0pt;font-family:"Arial","sans-serif";color:black;font-weight:bold;line-height:normal}span.bz{font-weight:normal}p.cc{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: center}span.bx{font-size:12.0pt;font-family:"Arial","sans-serif"}p.cd{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";line-height:115%}span.ce{color: black; font-div: italic; line-height: 115%}p.cf{margin:0cm;margin-bottom:.0001pt;line-height:120%;text-autospace:none;font-size:11.0pt;font-family:"Arial","sans-serif";color:black;font-weight:bold;text-align:justify;line-height:normal}p.cg{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";text-align:justify} span.bs{color:black}p.ch{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";font-weight: bold; text-align: justify}p.ci{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";margin-bottom:12.0pt;text-align:justify}span.bp{color: blue; text-decoration: underline}table.cj{width:444.2pt;margin-left:-5.4pt;border-collapse:collapse}tr.bi{height:21.15pt}td.bl{width:35.1%;padding:0cm 5.4pt 0cm 5.4pt;height:21.15pt}p.ck{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";font-weight: bold; page-break-after: avoid; text-align: justify; text-indent: -5.5pt}span.bn{font-size:10.0pt}td.bk{width:43.08%;padding:0cm 5.4pt 0cm 5.4pt;height:21.15pt} td.bj{width:21.82%;padding:0cm 5.4pt 0cm 5.4pt;height:21.15pt}tr.bc{height:19.85pt}td.bg{width:35.1%;padding:0cm 5.4pt 0cm 5.4pt; height:19.85pt}p.cl{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";text-indent:-5.5pt}td.bf{width:43.08%;padding:0cm 5.4pt 0cm 5.4pt; height:19.85pt}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";}td.bd{width:21.82%;padding:0cm 5.4pt 0cm 5.4pt; height:19.85pt}p.cm{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";text-align: right}td.bb{width:35.1%;padding:0cm 5.4pt 0cm 5.4pt;height:19.85pt}td.ba{width:43.08%;padding:0cm 5.4pt 0cm 5.4pt;height:19.85pt} td.az{width:21.82%;padding:0cm 5.4pt 0cm 5.4pt;height:19.85pt}span.ay{font-size:10.0pt;color:black}p.cn{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";font-weight: bold; page-break-after: avoid; text-indent: -5.5pt}p.co{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";text-indent:-5.5pt;}p.cp{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";text-autospace:none;vertical-align:middle}p.cq{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold}span.at{font-size:10.0pt;font-family:"Arial","sans-serif"}p.cr{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 115%}span.ar{font-size:10.0pt; line-height:115%;font-family:"Arial","sans-serif"} /**/
RNS Number : 0060S
AstraZeneca PLC
01 November 2019
 

1 November 2019 15:00 GMT

 

 

Transparency Directive

Voting Rights and Capital

 

The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 October 2019 the issued share capital of AstraZeneca PLC with voting rights is 1,311,904,600 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,311,904,600.

 

The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.

 

 

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Media Relations



Gonzalo Viña


+44 203 749 5916

Rob Skelding

Oncology

+44 203 749 5821

Rebecca Einhorn

Oncology

+1 301 518 4122

Matt Kent

BioPharmaceuticals

+44 203 749 5906

Jennifer Hursit

Other

+44 203 749 5762

Christina Malmberg Hägerstrand

Sweden

+46 8 552 53 106

Michele Meixell

US

+1 302 885 2677




Investor Relations



Thomas Kudsk Larsen


+44 203 749 5712

Henry Wheeler

Oncology

+44 203 749 5797

Christer Gruvris

BioPharmaceuticals (CV, Metabolism)

+44 203 749 5711

Nick Stone

BioPharmaceuticals (Renal), ESG

+44 203 749 5716

Josie Afolabi

BioPharmaceuticals (Respiratory),

other medicines

+44 203 749 5631

Craig Marks

Finance, fixed income

+44 7881 615 764

Jennifer Kretzmann

Corporate access, retail investors

+44 203 749 5824

US toll-free


+1 866 381 72 77

 

 

Adrian Kemp
Company Secretary

AstraZeneca PLC

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
TVRLLFVLLALLIIA

Quick facts: AstraZeneca

Price: 7217

Market: LSE
Market Cap: £94.68 billion
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE